Y-mAbs Therapeutics (NASDAQ: YMAB)
|Date||Analyst Firm||Analyst Name||Action||Rating||Action Price||Prior Price||Target|
You can purchase shares of Y-mAbs Therapeutics (NASDAQ: YMAB) through any online brokerage.
The latest price target for Y-mAbs Therapeutics (NASDAQ: YMAB) was reported by BMO Capital on Friday, June 24, 2022. The analyst firm set a price target for 27.00 expecting YMAB to rise to within 12 months (a possible 76.01% upside). 4 analyst firms have reported ratings in the last year.
The stock price for Y-mAbs Therapeutics (NASDAQ: YMAB) is $15.34 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for Y-mAbs Therapeutics.
Y-mAbs Therapeutics’s Q2 earnings are confirmed for Thursday, August 4, 2022.
There is no upcoming split for Y-mAbs Therapeutics.
Y-mAbs Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.